Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNPAT | O15228 | 1/20 | 0.44 |
| ▸ | CASP3 | P42574 | 6/20 | 0.43 |
| ▸ | CASP8 | Q14790 | 5/20 | 0.43 |
| ▸ | CASP1 | P29466 | 4/20 | 0.43 |
| ▸ | CASP7 | P55210 | 4/20 | 0.43 |
| ▸ | CASP9 | P55211 | 1/20 | 0.42 |
| ▸ | BACE1 | P56817 | 5/20 | 0.41 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.41 |
| ▸ | ENPEP | Q07075 | 5/20 | 0.40 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.40 |
| ▸ | BMP1 | P13497 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18037135 | 0.88 | CASP1 (0.43) | GNPATCASP3CASP1CASP7CASP9 | |
| SCHEMBL31468688 | 0.88 | BACE1 (0.46) | CASP3CASP8CASP1CASP7CASP9 | |
| SCHEMBL7157952 | 0.88 | GNPAT (0.44) | GNPATCASP3CASP8CASP1CASP7 | |
| SCHEMBL29576249 | 0.88 | GNPAT (0.44) | GNPATCASP3CASP8CASP1CASP7 | |
| SCHEMBL7166591 | 0.87 | GNPAT (0.48) | GNPATCASP3CASP8CASP1CASP7 | |
| SCHEMBL6534663 | 0.87 | GNPAT (0.54) | GNPATCASP3CASP1CASP7CASP9 | |
| SCHEMBL22310788 | 0.86 | GNPAT (0.47) | GNPATCASP3CASP8CASP1CASP7 | |
| SCHEMBL31634368 | 0.83 | KDM4E (0.51) | GNPATCASP3CASP1CASP7CASP9 | |
| SCHEMBL7165565 | 0.82 | CASP3 (0.55) | CASP3CASP8CASP1CASP7CASP9 | |
| SCHEMBL13194679 | 0.82 | CASP1 (0.50) | GNPATCASP3CASP8CASP1CASP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3525791-B1 | USE OF CASPASE-3 INHIBITORS AND CASPASE-3 ACTIVATORS IN THE MANUFACTURE OF MEDICAMENT FOR TREATING CANCER AND WOUND HEALING | TECHNION RES & DEV FOUNDATION (IL) | 2025-05-21 | — | — | EP | claimed |
| WO-2025127999-A1 | METHODS OF TREATING CHRONIC WOUNDS USING CASPASE INHIBITORS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2025-06-19 | — | — | WO | disclosed |
| EP-3525791-B1 | USE OF CASPASE-3 INHIBITORS AND CASPASE-3 ACTIVATORS IN THE MANUFACTURE OF MEDICAMENT FOR TREATING CANCER AND WOUND HEALING | TECHNION RES & DEV FOUNDATION (IL) | 2025-05-21 | — | — | EP | disclosed |
| CN-118853656-B | Urine sample stable protection liquid and application thereof in biomarker detection | 南京欧际医药科技服务有限公司 | 2025-01-28 | — | — | CN | disclosed |
| EP-4493275-A1 | METHODS AND COMPOSITIONS FOR IMPROVING IN VIVO SURVIVAL OF MIDBRAIN DOPAMINE NEURONS | Memorial Sloan Kettering Cancer Center (US) | 2025-01-22 | — | — | EP | disclosed |
| US-20250017979-A1 | METHODS AND COMPOSITIONS FOR IMPROVING IN VIVO SURVIVAL OF MIDBRAIN DOPAMINE NEURONS | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2025-01-16 | — | — | US | disclosed |
| US-12133720-B2 | Methods and compositions for restoring homeostatic capacity of a subject | Palo Alto Investors LP (US) | 2024-11-05 | — | — | US | disclosed |
| CN-118853656-A | Urine sample stable protection liquid and application thereof in biomarker detection | 南京欧际医药科技服务有限公司 | 2024-10-29 | — | — | CN | disclosed |
| WO-2023177919-A1 | METHODS AND COMPOSITIONS FOR IMPROVING IN VIVO SURVIVAL OF MIDBRAIN DOPAMINE NEURONS | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2023-09-21 | — | — | WO | disclosed |
| CN-115947807-A | Transcription factor for regulating programmed death of plant cell and application thereof | 广西大学 | 2023-04-11 | — | — | CN | disclosed |
| WO-2022190064-A1 | METHODS FOR IDENTIFYING SUBJECTS WITH BETACORONAVIRUS INFECTIONS WHO ARE AT RISK OF ACUTE RESPIRATORY SYNDROME AND METHODS FOR THE TREATMENT OF SAME | VEXO PHARMACEUTICALS DMCC (AE) | 2022-09-15 | — | — | WO | disclosed |
| EP-3049530-B1 | METHOD FOR CELL-FREE PROTEIN SYNTHESIS IN THE PRESENCE OF A CASPASE INHIBITOR | FRAUNHOFER GES FORSCHUNG (DE) | 2022-06-22 | — | — | EP | disclosed |
| CN-114456243-A | Peanut functional protein AhUB4 and coding gene and application thereof | 广西大学 | 2022-05-10 | — | — | CN | disclosed |
| US-11291705-B2 | Use of caspase-3 inhibitors and caspase-3 activators in the manufacture of medicament for treating cancer and wound healing | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) | 2022-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250017979-A1 | METHODS AND COMPOSITIONS FOR IMPROVING IN VIVO SURVIVAL OF MIDBRAIN DOPAMINE NEURONS | CHAT, PINK1, DBH | GNPAT 2847/4885CASP3 15/4885CASP8 319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.